Overview

A Study to Evaluate the Effect of IMB-1018972 on Cardiac Energetics in Patients With Type 2 Diabetes (IMPROVE-DiCE)

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
Phase:
Phase 2
Details
Lead Sponsor:
Imbria Pharmaceuticals, Inc.
Collaborator:
University of Oxford